Clinical Trial: Tigecycline In-Vitro Surveillance Study In Taiwan
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Tigecycline In-Vitro Surveillance Study In Taiwan
Brief Summary: In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome:
- Prior to 2009: Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90by pathogen, tested by E-test. [ Time Frame: in vitro study therefore not applicable ]
- Post-2009: Susceptibility data of MIC, MIC50, MIC90 by pathogen, tested by micro-dilution method [ Time Frame: in vitro study therefore not applicable ]
Original Primary Outcome:
Current Secondary Outcome:
- Prior to 2009: 1. Susceptibility data of minimum inhibitory concentration (MIC), MIC50, MIC90 by pathogen, tested by micro-dilution method 2. Susceptibility data of inhibition zone diameter(mm) by pathogen, tested by paper disc. [ Time Frame: in vitro study therefore not applicable ]
- Post-2009: Susceptibility data of inhibition zone diameter (mm) by pathogen, tested by paper disc. [ Time Frame: in vitro study therefore not applicable ]
Original Secondary Outcome:
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: June 18, 2007
Date Started: August 2006
Date Completion:
Last Updated: March 21, 2011
Last Verified: March 2011
